Status:
COMPLETED
Effectiveness of SMS Reminders on Influenza Vaccination Coverage in Patients With RA in the ART Registry
Lead Sponsor:
Societe Francaise de Rhumatologie
Collaborating Sponsors:
Assistance Publique - Hôpitaux de Paris
University Hospital, Toulouse
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Biotherapies have significantly improved the prognosis of rheumatoid arthritis (RA), particularly anti-TNF. However, these molecules are associated with a well-demonstrated increase in infectious risk...
Detailed Description
Design : Randomised, controlled trial within the e-cohort population of the French ART registry (observational study) Target population : All participants to the e-cohort of the French ART Registry...
Eligibility Criteria
Inclusion
- All patients included in the French ART Registry (rheumatoid arthritis and anti-TNF) and participating to the e-cohort.
- Adult patients with RA,
- Patient in whom the specialist physician decides to start treatment with an anti-TNF drug, regardless of the treatment line and regardless of the anti-TNF, including infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according to their arrival on the market
- Clinicians (hospital-based and private practice) who agree to adhere to the yearly renewal of the hospital prescription
Exclusion
- Patient already treated by the same anti-TNF in the past (same drug)
Key Trial Info
Start Date :
October 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
446 Patients enrolled
Trial Details
Trial ID
NCT05220423
Start Date
October 19 2021
End Date
April 30 2022
Last Update
October 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Bicêtre
Le Kremlin-Bicêtre, France